Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Alcoholism: Clinical and Experimental Research

• Publication date

  2009-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1530-0277.2009.00925.xPMID 19302083PMCID PMC4625790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Opioid antagonists for alcohol dependence.

  2010cited by this paper
• National Survey on Drug Use and Health

  2009cited by this paper
• Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions

  2009cited by this paper
• Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.

  2009cited by this paper
• Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration

  2008cited by this paper
• The Impact of Depressive Symptoms on the Efficacy of Naltrexone in Smoking Cessation

  2008cited by this paper
• Treating Tobacco Use and Dependence: 2008 Update

  2008cited by this paper
• Tobacco chippers show robust increases in smoking urge after alcohol consumption

  2007cited by this paper
• Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment.

  2007cited by this paper
• Pharmacological effects of naltrexone and intravenous alcohol on craving for cigarettes among light smokers: a pilot study

  2007cited by this paper
• Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking

  2007cited by this paper
• Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking.

  2007cited by this paper
• Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences.

  2006influential reference
• Differential effects of nicotine on alcohol consumption in men and women

  2006cited by this paper
• The Status of Naltrexone in the Treatment of Alcohol Dependence: Specific Effects on Heavy Drinking

  2006cited by this paper
• Opioid antagonists for smoking cessation.

  2006cited by this paper
• A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation.

  2006cited by this paper
• Alcohol dose-dependent increases in smoking urge in light smokers.

  2005cited by this paper
• Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.

  2004cited by this paper
• Measures of abstinence in clinical trials: issues and recommendations.

  2003cited by this paper
• Naltrexone treatment for alcoholics: effect on cigarette smoking rates.

  2003cited by this paper
• Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation.

  2002cited by this paper
• Body weight, alcohol consumption and liver enzyme activity--a 4-year follow-up study.

  2001cited by this paper
• The role of biomarkers in alcoholism medication trials.

  2001cited by this paper
• Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline.

  2000cited by this paper
• Effects of naltrexone on alcohol self-administration in heavy drinkers.

  1999cited by this paper
• Naltrexone effects on short-term and long-term smoking cessation.

  1999cited by this paper
• Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence.

  1999cited by this paper
• Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.

  1999cited by this paper
• Naltrexone biotransformation and incidence of subjective side effects: a preliminary study.

  1997cited by this paper
• The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group.

  1997cited by this paper
• Naltrexone and alcohol dependence. Role of subject compliance.

  1997cited by this paper
• Structured Clinical Interview for DSM-IV Axis I Disorders

  1997cited by this paper
• Experience of a "slip" among alcoholics treated with naltrexone or placebo.

  1996cited by this paper
• First lapses to smoking: within-subjects analysis of real-time reports.

  1996cited by this paper
• Naltrexone increases the latency to drink alcohol in social drinkers.

  1996cited by this paper
• A Risk-Benefit Assessment of Naltrexone in the Treatment of Alcohol Dependence

  1996cited by this paper
• Effect of naltrexone on alcohol "high" in alcoholics.

  1995cited by this paper
• Drinking and Smoking: a Field Study of their Association

  1994cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1994cited by this paper
• Naltrexone-induced alterations in human ethanol intoxication.

  1994cited by this paper
• Naltrexone in the treatment of alcohol dependence.

  1992cited by this paper
• The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

  1991cited by this paper
• Slip-ups and relapse in attempts to quit smoking.

  1990cited by this paper
• High-dose naltrexone therapy and dietary counseling for obesity.

  1987influential reference
• The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.

  1986cited by this paper
• Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage.

  1986cited by this paper
• Longitudinal data analysis using generalized linear models

  1986cited by this paper
• Reliability of alcohol abusers' self-reports of drinking behavior.

  1979cited by this paper

• The pharmaceutically enhanced reinforcement for reduced alcohol and smoking (PERRAS) study: Protocol for a randomized clinical trial.

  2025cites this paper
• Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

  2025cites this paper
• Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.

  2022cites this paper
• The incentive amplifying effects of nicotine: Roles in alcohol seeking and consumption.

  2022cites this paper
• Pharmacological interventions on smoking cessation: A systematic review and network meta-analysis

  2022cites this paper
• Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.

  2021cites this paper
• The effects of pharmacological interventions on smoking cessation in people with alcohol dependence: A systematic review and meta‐analysis of nine randomized controlled trials

  2021cites this paper
• Targeting the Opioid Receptors: A Promising Therapeutic Avenue for Treatment in "Heavy Drinking Smokers".

  2021cites this paper
• Combined varenicline and naltrexone attenuates alcohol cue-elicited activation in heavy drinking smokers.

  2021cites this paper
• A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder.

  2020cites this paper
• Nicotine and Opioids: a Call for Co-treatment as the Standard of Care

  2020cites this paper
• Nicotine increases alcohol self‐administration in male rats via a μ‐opioid mechanism within the mesolimbic pathway

  2020cites this paper
• DEVELOPMENT OF A TRANSLATIONAL MODEL OF CO-USE OF ALCOHOL AND NICOTINE FOR TESTING POTENTIAL PHARMACOTHERAPIES

  2019cites this paper
• Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial.

  2019cites this paper
• An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDI.

  2018cites this paper
• Nicotine‐Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence

  2018cites this paper
• Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status

  2017cites this paper
• The Effects of Naltrexone on Neural Responses to Methamphetamine Cues

  2017cites this paper
• Endogenous opioid system: a promising target for future smoking cessation medications

  2017cites this paper
• A Critical Review of the Effects of Nicotine and Alcohol Coadministration in Human Laboratory Studies

  2017cites this paper
• A Call to Arms: The Role of the Psychiatry Resident in the Current Opioid Epidemic

  2016cites this paper
• MEDICAL TREATMENT OF ALCOHOL DEPENDENCE

  2016cites this paper
• Smokers' Treatment Expectancies Predict Smoking Cessation Success.

  2016cites this paper
• Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse.

  2016cites this paper
• Current Insights into the Mechanisms and Development of Treatments for Heavy-Drinking Cigarette Smokers

  2016cites this paper
• Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings

  2015cites this paper
• Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers

  2015cites this paper
• Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.

  2015cites this paper
• Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task

  2014cites this paper
• Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.

  2014influential citation
• Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings

  2014cites this paper
• Title Varenicline , low dose naltrexone , and their combination for heavy-drinking smokers : human laboratory findings Permalink

  2014cites this paper
• Pharmacological Approaches to the Treatment of Alcohol Dependence in the Young

  2014cites this paper
• Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse

  2014cites this paper
• Predictors of Interest in an Alcohol Reduction Clinical Trial of Naltrexone among Undergraduates

  2013cites this paper
• Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.

  2013cites this paper
• Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.

  2013cites this paper
• 2013 Update in addiction medicine for the generalist

  2013cites this paper
• Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists.

  2012cites this paper
• Current progress in pharmacologic treatment strategies for alcohol dependence

  2012cites this paper
• Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.

  2012cites this paper
• Depot naltrexone decreases rewarding properties of sugar in patients with opioid dependence

  2011cites this paper
• Pharmacotherapy for Alcoholism and Some Related Psychiatric and Addictive Disorders: Scientific Basis and Clinical Findings

  2010cites this paper
• The Pharmacotherapy of Alcohol Dependence: A State of the Art Review

  2010cites this paper
• Simultaneous versus Delayed Treatment of Tobacco Dependence in Alcohol-Dependent Outpatients

  2010cites this paper
• Endogenous opiates and behavior: 2009.

  2010cites this paper
• Endogenous opioids and addiction to alcohol and other drugs of abuse.

  2009cites this paper